Aspen subsidiary Pharmacare, which trades as Aspen Pharmacare, has entered into a preliminary agreement with Janssen Pharmaceuticals and Janssen Pharmaceutica for the technical transfer and proposed commercial manufacture of their Covid-19 vaccine candidate, Ad26.COV2-S. The agreement is still subject to the successful completion of the relevant technology transfer activities and finalisation of certain commercial manufacturing terms, but Aspen Pharmacare has agreed to provide the necessary capacity required for the manufacture of Johnson & Johnson’s Covid-19 vaccine candidate at its existing sterile facility in Port Elizabeth,.
from Engineering News | Home https://ift.tt/2TMtYK4
